论文部分内容阅读
目的分析美托洛尔联合厄贝沙坦治疗心力衰竭的临床效果。方法 100例心力衰竭患者,随机分为对照组和观察组,各50例。对照组给予美托洛尔缓释片治疗,观察组在对照组基础上给予厄贝沙坦治疗,比较两组疗效。结果观察组总有效率为96%,高于对照组的84%,差异具有统计学意义(P<0.05)。治疗后观察组左室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)均优于对照组,差异具有统计学意义(P<0.05)。结论对心力衰竭患者除美托洛尔缓释片治疗外,联用厄贝沙坦治疗疗效更好,在临床治疗中起显著作用。
Objective To analyze the clinical effect of metoprolol combined with irbesartan in the treatment of heart failure. Methods 100 cases of heart failure patients were randomly divided into control group and observation group, 50 cases each. The control group was given metoprolol sustained-release tablets. The observation group was treated with irbesartan on the basis of the control group. The curative effect was compared between the two groups. Results The total effective rate in observation group was 96%, which was higher than 84% in control group, the difference was statistically significant (P <0.05). The left ventricular ejection fraction (LVEF), left ventricular end-diastolic dimension (LVEDD) and left ventricular end-systolic diameter (LVESD) in the observation group after treatment were all better than those in the control group, with statistical significance (P <0.05). Conclusion In addition to metoprolol sustained-release tablets, heart failure patients treated with irbesartan have a better effect and play a significant role in clinical treatment.